Kerri Fitzgerald

DocwireNews

Researchers conducted a post-hoc analysis of the prospective, phase III HAWK and HARRIER trials to assess the efficacy and safety of brolucizumab versus aflibercept in patients with wet age-related macular degeneration (AMD). Fewer brolucizumab injections were required to achieve sustained dryness over a 96-week period, and sustained dryness was achieved faster and more frequently in brolucizumab-treated patients. The results of the study were published as part of the American Society of Retina Specialists 2020 Virtual Annual Meeting.Patients were randomized to receive brolucizumab 3 mg (from the HAWK trial only) or 6 mg (via three loading doses, followed by treatment every 12 weeks, with an option to adjust to every eight weeks if disease activity was present) or aflibercept 2 mg (every eight weeks). Sustained dryness was defined as three or more consecutive fluid-free visits (defined as absence of both intraretinal fluid and subretinal fluid) at the 50th and 75th percentiles.Sustained dryness was achieved faster with brolucizumab than aflibercept in both clinical trials. At week 96, a higher proportion of patients receiving brolucizumab achieved sustained dryness compared with aflibercept, and sustained dryness was also achieved to a greater degree in brolucizumab-treated patients. Fewer brolucizumab injections were required to achieve the 50th&nbsp;percentile and 75th&nbsp;percentile for sustained dryness from baseline.&ldquo;Having a more durable drug allows for a potential of optimal visual outcomes with less treatment burden,&rdquo; the authors noted. &ldquo;These outcomes suggest that brolucizumab treatment results in better disease control than aflibercept, thereby potentially reducing the treatment burden in wet AMD in the long term.&rdquo;Regillo CD, Wyckoff CC, Yang Y, et al. Number of Injections and Time to Dry Analysis of Brolucizumab Versus Aflibercept in Patients with Neovascular AMD: 96-Week Data From HAWK and HARRIER. Presented during the ASRS 2020 Virtual Annual Meeting, July 24-26, 2020.

Jordana Jampel

Cutaneous Melanoma: Sun Protection Behaviors and UV Exposure in Canada

Melanoma

Leah Lawrence

Significant Cardiac Benefit Seen With Ifetroban in Patients With Duchenne Muscular Dystrophy

Neurology

Apitegromab Improved Motor Function in Type 2/3 Spinal Muscular Atrophy

Latest News

Number of Brolucizumab Versus Aflibercept Injections Needed to Sustain Dryness in Patients with Wet AMD

ASRS 2020

Researchers conducted a post-hoc analysis of the prospective, phase III HAWK and HARRIER trials to assess the efficacy and safety of brolucizumab versus aflibercept in ...

Number of Brolucizumab Versus Aflibercept Injections Needed to Sustain Dryness in Patients with Wet

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe